• pigmented villonodu
  • This study, designed as a proof of concept study of MCS110 in pigmented villonodular synovitis, will assess the clinical response to MCS110 treatment in Pigmented Villonodular Synovitis (PVNS) and Giant cell tumor of the tendon sheath (GCTTS) patients after multiple intravenous doses of MCS110 using magnetic resonance imaging to assess tumor volume, and to evaluate pharmacokinetics/pharmacodynamics, safety and tolerability in this population. (clinicaltrials.gov)
  • PVNS
  • Primary endpoint is assessment of efficacy of multiple i.v. doses of MCS110 in reducing the volume of PVNS or GCTTS tumors evaluated by MRI after 8 weeks post last dose. (clinicaltrials.gov)
  • Patients
  • From January 2010 to October 2014, 30 patients with benign tumor in proximal femur were treated with debridement, autogenic ilium, autogenic ilium and allogeneic bone implant, and anatomic plate fixation. (readbyqxmd.com)